Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;231(11):2291-8.
doi: 10.1007/s00213-013-3378-0. Epub 2014 Jan 9.

Serotonin-1A Receptor Stimulation Mediates Effects of a Metabotropic Glutamate 2/3 Receptor Antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic Acid (LY341495), and an N-methyl-D-aspartate Receptor Antagonist, Ketamine, in the Novelty-Suppressed Feeding Test

Affiliations

Serotonin-1A Receptor Stimulation Mediates Effects of a Metabotropic Glutamate 2/3 Receptor Antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic Acid (LY341495), and an N-methyl-D-aspartate Receptor Antagonist, Ketamine, in the Novelty-Suppressed Feeding Test

Kenichi Fukumoto et al. Psychopharmacology (Berl). .

Abstract

Rationale: α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor stimulation has been proposed to be a common neural mechanism of metabotropic glutamate 2/3 (mGlu2/3) receptor antagonists and an N-methyl-D-aspartate receptor antagonist, ketamine, exerting antidepressant effects in animal models. AMPA receptor stimulation has also been shown to mediate an increase in the extracellular level of serotonin (5-HT) in the medial prefrontal cortex by an mGlu2/3 receptor antagonist in rats. However, involvement of the serotonergic system in the actions of mGlu2/3 receptor antagonists and ketamine is not well understood.

Objectives: We investigated involvement of the serotonergic system in the effects of an mGlu2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and ketamine in a novelty-suppressed feeding (NSF) test in mice.

Results: The intraperitoneal administration of LY341495 or ketamine at 30 min prior to the test significantly shortened latency to feed, which was attenuated by an AMPA receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydr-obenzo[f]quinoxaline-7-sulfonamide (NBQX). The effects of LY341495 and ketamine were no longer observed in mice pretreated with a tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA). Moreover, the effects of LY341495 and ketamine were blocked by a 5-HT1A receptor antagonist, N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl) cyclohexane-carboxamide (WAY100635), but not by a 5-HT2A/2C receptor antagonist, ritanserin. Likewise, an AMPA receptor potentiator, 2,3-dihydro-1,4-benzodioxin-7-yl-(1-piperidyl)methanone (CX546), shortened latency to feed in the NSF test, which was prevented by depletion of 5-HT and blockade of 5-HT1A receptor.

Conclusions: These results suggest that AMPA receptor-dependent 5-HT release and subsequent 5-HT1A receptor stimulation may be involved in the actions of an mGlu2/3 receptor antagonist and ketamine in the NSF test.

Similar articles

See all similar articles

Cited by 21 articles

See all "Cited by" articles

References

    1. Biol Psychiatry. 2008 Feb 15;63(4):349-52 - PubMed
    1. Neuropharmacology. 2003 Dec;45(8):1050-6 - PubMed
    1. J Pharmacol Exp Ther. 2000 Jan;292(1):76-87 - PubMed
    1. Behav Brain Res. 2013 Feb 1;238:48-52 - PubMed
    1. Psychopharmacology (Berl). 2007 Feb;190(2):233-9 - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback